The Chronic Lymphocytic Leukemia Comorbidity Index (Cll-Ci): A Novel Comorbidity Score Derived From A Large Multicenter Retrospective Cohort Study Of Patients Treated With Ibrutinib And/Or Chemo-Immunotherapy (Cit)

Introduction: Outcomes in CLL are highly variable and influenced by both biologic and clinical factors. The Cumulative Illness Rating Scale (CIRS) is frequently used to assess comorbidities in CLL. Our group has demonstrated that CIRS correlates with survival in patients treated with either CIT or ibrutinib. Yet, CIRS has not become part of common clinical practice due to complexities in scoring since 14 systems need to be evaluated. Furthermore, the relative contribution of individual comorbidities to patient outcomes is unknown. Here we report the impact of specific comorbidities in a large cohort of CLL patients and propose a simplified CLL-comorbidity index (CLL-CI).